Our federal Government of Canada has signed a bilateral agreement with the Government of Ontario to enhance access to drugs for rare diseases. This agreement, which represents an investment of over $535 million, aims to improve the affordability and availability of essential medications for individuals living with rare diseases in Ontario.
In Canada, 1 in 12 people are affected by rare diseases, and the cost of treatment can be prohibitively expensive. This new agreement will provide funding to support access to five critical drugs under the National Strategy for Drugs for Rare Diseases: Poteligeo, Oxlumo, Epkinly, Welireg, and Yescarta. These medications are vital for treating conditions such as mycosis fungoides, hyperoxaluria type 1, diffuse large B-cell lymphoma, von Hippel-Lindau disease, and various types of lymphoma.
MP Sonia Sidhu stated, "This agreement is a significant step forward in ensuring that individuals in Brampton South and across Ontario have access to the life-saving medications they need. By investing in these drugs, we are not only improving health outcomes but also providing hope to families affected by rare diseases."
In addition to improving access to medications, the agreement includes a commitment to enhance early diagnosis and screening for rare diseases. Ontario will work collaboratively with the federal government and other provinces and territories to develop and implement a comprehensive plan for better screening and diagnostics. “The Government of Canada remains dedicated to working with provinces and territories to build a stronger public health system," said MP Sidhu."This agreement reflects our commitment to ensuring that all Canadians, regardless of where they live or their financial situation, can access the treatments they need for a better quality of life."
The Honourable Mark Holland, Canada's Minister of Health, added, "Reaching these agreements is another step in our collaborative efforts to build a stronger public health system for Ontarians. By investing in drugs for rare diseases, this agreement will improve affordability and access to medications, early diagnosis, and screening, so that people in Ontario with rare diseases have the best health outcomes possible"